Webinar | Is your natural food dye compliant, shelf-stable, and ready to scale?
24th July | 12 PM ET: Register Now
Webinar | Is your natural food dye compliant, shelf-stable, and ready to scale?
24th July | 12 PM ET: Register Now
When a single patent attracts 17 separate oppositions at the European Patent Office, it signals more than just legal friction. In the pharmaceutical market, this could signal a billion-dollar market
University labs are becoming key sources of licensable intellectual property in the video coding industry. Over 1,400 VVC-related patent families are linked to just a few leading universities, including Peking
Novo Nordisk’s Canadian Patent CA 2601784 (Acylated GLP-1 Compounds), protecting Ozempic and Wegovy’s active ingredient, semaglutide, has lapsed. This event, linked to the non-payment of a maintenance fee, has drawn
The networking industry is undergoing a technological renaissance, driven by innovations in wireless communication, cloud computing, and secure data transmission. As patent filings surge and litigation trends evolve, companies and
Ofinno is known for declaring patents as SEPs and actively engaging in licensing activities. So, when Comcast transferred over 30 wireless communication patents to them, we dived right into the
Several high-value drug patents are expiring as early as February 2025, along with their data exclusivities. The list includes Farxiga, Mounjaro, and Ozempic, opening a window for generic developers to
In 2023, nChain announced a partnership with Japan’s FinTeK (Keio University) to expedite the adoption of blockchain technology in the region. This collaboration showcases nChain’s strategy to broaden its influence
With an average life expectancy of 3-5 years after diagnosis, Pulmonary fibrosis highlights an urgent need for innovative therapeutic interventions. That’s where medications like Ofev have emerged as a transformative
Trajenta, known for its effective glycemic control without weight gain, is a key player in the diabetes medication sector. This critical medication, known generically as Linagliptin, is on the brink
The European Patent Office (EPO) receives more than 2000 oppositions each year, directly impacting the future success and exclusivity of pharmaceutical products. Monitoring the outcomes of these oppositions is crucial
While numerous drugs for diabetes are available in the market, many come with undesirable side effects such as weight gain, hypoglycemia, and hypertension. However, a game-changing solution has been introduced
The arthritis treatment industry is characterized by its intense competitiveness, driving companies to invest significantly in research and development to secure leading arthritis drug patents. Consequently, the expiration of patents
More than 500 million people around the world are affected by diabetes, and this issue is intensified by a surging obesity crisis, particularly in wealthier nations. In such a crisis,
The fiercely competitive nature of the oncology industry makes the companies invest heavily in research and development to bring in top cancer-treating drug patents. Consequently, the expiration of patents for
Given the competitive nature of the pharmaceutical domain, the expiration of drug patents presents significant opportunities, particularly for companies specializing in generic medications. Pharmaceutical companies seeking to expand or diversify
A patent family is an unparalleled fortress, strategically safeguarding intellectual property across multiple jurisdictions. It forms a robust defense, enabling swift and global protection against unauthorized use of innovative concepts.
